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Abstract  19 
Aims: This study explores the impact of paediatric patient related factors and choice of 20 
formulation on the dissolution characteristics of nifedipine and lorazepam, two drug substances 21 
regularly applied in very young patients and in compounded formulations.  22 
Methods:  Dissolution experiments were designed to reflect clinical practice in a paediatric 23 
hospital, with respect to dosage forms, feeding regimens, and methods of administration. 24 
Solubility studies addressed the influence of age and prandial state. Drug solubility and 25 
dissolution experiments were conducted in biorelevant media and adapted age-specific (neonate 26 
and infant) media. Dissolution studies were performed with the mini-paddle apparatus and the 27 
flow-through cell apparatus.  28 
Results: Dissolution of nifedipine formulations was not affected by age-related changes of the 29 
fasted state simulated gastro-intestinal fluids, and by disintegration of the formulation before 30 
administration. However, a significant difference in nifedipine’s dissolution rate from 31 
commercial tablets and compounded capsules was observed. The dissolution of lorazepam 32 
tablets was affected by fasted- vs. fed-state media, but it was deemed less likely to be clinically 33 
relevant. The significant effect of fed-state media on nifedipine’s solubility was considered to 34 
have possible clinical relevance since very young patients are almost continuously in a fed state.  35 
Conclusion: The in vitro results obtained from these studies reveal the potential of biorelevant 36 
solubility and dissolution studies reflecting clinical practice to predict drug performance in 37 
paediatric patients. 38 
  39 
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What is already known: 42 
 Using biorelevant dissolution, successful in vitro in vivo relations/correlations (IVIVCs) 43 
have been established for oral immediate and modified release formulations in adults 44 
 Evaluation of oral drug absorption is often only performed for fasted state conditions, 45 
which are not applicable to new-borns and infants. 46 
What this research adds: 47 
 In vitro dissolution tests were conducted for two nifedipine formulations under settings 48 
considered to reflect clinical conditions. Both nifedipine conventional commercial 49 
tablets and compounded capsules displayed slow dissolution in fasted state conditions. 50 
 Our biorelevant solubility results suggest that there is a food effect on the solubility of 51 
nifedipine in gastrointestinal fluids in neonates and infants, which might be translated 52 
into an effect on in vivo drug absorption after administration of conventional 53 
formulations. 54 
 55 
  56 
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1. Introduction 57 
During the last decades, the purpose of dissolution testing of drugs has expanded from pure 58 
quality control to prediction of in vivo drug performance and identifying potential 59 
bioavailability problems of pharmaceutical formulations. With development of biorelevant 60 
dissolution media (reflecting the main properties of gastrointestinal fluids), simulation of 61 
gastro-intestinal residence times, and simulation of gastro-intestinal hydrodynamics, successful 62 
in vitro in vivo relations and correlations (IVIVRs/ IVIVCs) have been established for oral 63 
immediate and modified release formulations in adults, using compendial dissolution apparatus 64 
[1], [2]. Furthermore, in vitro dissolution data are used as input in physiologically based 65 
pharmacokinetic (PBPK) prediction models in which different factors influencing drug 66 
absorption are integrated. Both biorelevant dissolution and PBPK modelling are regularly 67 
applied in drug development by the pharmaceutical industry, i.e. to select and optimize 68 
formulations, or to predict solubilisation and precipitation in the human gastro-intestinal tract 69 
under various conditions [3]. Ideally, in vitro predictive methods, combined with in silico 70 
models, will replace in vivo experiments and clinical trials.  71 
In recent years, advances towards the availability of suitable paediatric biorelevant dissolution 72 
tests have been made with the development of paediatric media [4]. These media were based 73 
on the available literature on the composition of paediatric luminal fluids and the established 74 
adult media [5]. Experimental dissolution parameters that mimic paediatric conditions have 75 
been proposed [6], [7]. The search for alternatives to clinical trials is essential, especially in 76 
paediatrics, given the ethical and methodological difficulties involved in performing trials in 77 
paediatric patients [8]. Predictive biopharmaceutical methods representing the in vivo drug 78 
dissolution in children would be of huge benefit for early formulation screening and assessing 79 
the influence of different administration strategies on drug performance, with the ultimate goal 80 
to reduce the amount of in vivo studies required and accelerating paediatric drug development.  81 
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Apart from the obvious differences between children and adults regarding the physiological 82 
development of the gastro-intestinal tract, the effect of pharmacotherapy in paediatric patients 83 
can be further influenced by a range of patient-related factors, such as feeding regimens, the 84 
presence of feeding tubes, immobility, and the selected drug formulation. Pharmacists often 85 
have to rely on extemporaneous compounding and unlicensed manufacturing, or manipulation 86 
of adult dosage forms, in case licensed, age-appropriate paediatric drug products are not 87 
available. 88 
This study aims to explore the application of biopharmaceutical methods to study the impact of 89 
patient related factors on drug performance in paediatric patients, using two biopharmaceutical 90 
tools:  drug substance solubility and drug product dissolution in biorelevant media adapted to 91 
reflect paediatric conditions. Dissolution experiments were designed to simulate the impact of 92 
formulation handling and dosage form manipulation. Dissolution parameters were set based on 93 
what is currently known about physiological conditions in the GI tract of children. To assess 94 
the age- and prandial state related changes in paediatric gastrointestinal solubility, respective 95 
studies were performed in both adult biorelevant media and adapted paediatric media.  96 
The compounds that were chosen to be studied were nifedipine and lorazepam, as they are both 97 
regularly applied in unlicensed formulations and in very young patients. Nifedipine is a 98 
biopharmaceutical classification system (BCS) class II drug substance, with an aqueous 99 
solubility of around 5-9 µg/ml [9] and a logP value of 2.20 [10]. With pKa values of -0.9 and 100 
13, it is not ionisable in the gastro-intestinal pH range. Therefore, under physiologically relevant 101 
conditions, nifedipine acts as a neutral molecule and its solubility is independent of the pH of 102 
the medium [11]. Lorazepam is a compound with a slightly better aqueous solubility (80 µg/ml) 103 
compared to nifedipine, and a logP value of 2.39 [12]. With pKa values of 1.3 and 11.5 [13], it 104 
can be partly ionised within the acidic conditions of the fasted stomach. Using the above stated 105 
Page 6 of 37 
  
solubility value, a dose number (D0) ≤ 1 is calculated for dose strengths up to 20 mg, and thus 106 
lorazepam would be considered as a highly soluble, class I compound within the ‘adult’ BCS.   107 
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2. Materials and methods 108 
2.1. Materials 109 
Pepsin from porcine gastric mucosa (powder, ≥400 units/mg protein), nifedipine drug substance 110 
(≥98% HPLC grade), lorazepam reference standard (≥98% HPLC grade) and Whatman GF/D 111 
(pore size 2.7 μm, 25 mm diameter) and GF/F (pore size 0.7 μm, 25 mm diameter) filters were 112 
purchased from Sigma–Aldrich (Dorset, UK). UHMW polyethylene 10 micron full flow 113 
cannula filters were bought from Quality Lab Accessories LCC (Telford, USA). Egg-lecithin 114 
(Lipoid E PCS) was purchased from Lipoid GmbH (Ludwigshafen, Germany). Sodium 115 
taurocholate (NaTc) was purchased from Prodotti Chimici e Alimentari S.p.A (Basaluzzo, AL, 116 
Italy). Cronus 13 mm regenerated cellulose (RC) syringe filters 0.45 µm were purchased from 117 
LabHut Ltd (Maisemore, UK). Aptamil 1 (Nutricia, Trowbridge, UK), SMA Wysoy Soya 118 
Infant Formula (SMA Nutrition, Gatwick, UK) and Ultra Heat Treated Standardised Whole 119 
Milk 3.6% fat (Sainsbury’s, London, UK) were purchased from a local supermarket. Water was 120 
of Milli-Q grade. All other reagents and chemicals were of analytical grade and were used as 121 
received, without further purification.  122 
2.2.  Instrumentation 123 
Equipment utilized in the current study included a R114 Rotavapor (Buchi, Flawil, 124 
Switzerland), a SevenCompact pH/Ion S220 pH meter (Mettler-Toledo AG, Schwerzenbach, 125 
Switzerland), Heraeus Fresco 17 and Heraeus Biofuge Primo R centrifuges (Thermo Scientific, 126 
Hanau, Germany), an Agilent Technologies 708-DS (USP II) apparatus configured with Agilent 127 
TruAlign 200 ml vessels and Agilent electropolished stainless steel mini-paddles (Santa Clara, 128 
CA), a Sotax CE7 smart flow-through cell (USP IV) apparatus connected to a CP 7 Piston Pump 129 
(Sotax, Switzerland). The Agilent 1100 HPLC system consisted of a G1311A Quaternary 130 
Pump, G1315A DAD detector, G1316A Column Compartment, G1322A Degasser, G1329A 131 
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Autosampler, G1330A Autosampler Thermostat and ChemStation® software (Agilent 132 
Technologies, Santa Clara, US). 133 
2.3. Drug products 134 
Conventional commercial nifedipine “retard” 10 mg tablets (Centrafarm, Etten-Leur, the 135 
Netherlands), unlicensed GMP-grade nifedipine 1 and 5 mg capsules (Apotheek A15, 136 
Gorinchem, the Netherlands), commercial lorazepam 1 mg IR tablets (Mylan, Bunschoten, The 137 
Netherlands) and unlicensed GMP-grade lorazepam oral solution 1 mg/ml (Apotheek A15, 138 
Gorinchem, the Netherlands) were used. Nifedipine capsules were compounded from pure API 139 
into hard gelatine capsules using lactose as single excipient. Lorazepam oral solution 1 mg/ml 140 
contains glycerol 85%v/v (87%v/v), polyethylene glycol (PEG) 400 (10%v/v) and propylene 141 
glycol (3%v/v) [14]. All formulations used in this study were part of the formulary of the Sophia 142 
Children’s Hospital, Rotterdam, The Netherlands.  143 
Although no dosing advice is available for neonates, in clinical practice nifedipine is sometimes 144 
administered to patients below the age of one month, in dosages from 0.1 up to 1.0 mg/kg [25]. 145 
For experiments simulating neonatal or infant conditions, nifedipine unlicensed 1 mg capsules 146 
were used to reflect clinical practice. 147 
Oral lorazepam is used off-label to gradually taper-off benzodiazepines that have been 148 
administered as continuous intravenous sedation at the paediatric intensive care unit (PICU). It 149 
is usually administered 4 times daily, in single dosages up to 0.5 mg (neonates), 1 mg (infants) 150 
and 3 mg (children) [15]. To allow for precise dosing and ease of administration, a 1 mg/ml 151 
oral solution was developed specifically for paediatric patients [14].  152 
2.4. Media used for solubility and dissolution studies 153 
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Simulated Gastric Fluid without pepsin (SGF sp) pH 1.2 and Simulated Intestinal Fluid without 154 
pancreatin (SIF sp) pH 6.8 were used in dissolution studies [16]. Freshly prepared adult and 155 
age-specific (neonate and infant) biorelevant media were used in solubility and dissolution 156 
studies (Table 1) [4], [5], [16], [17].  157 
2.5. In vitro dissolution studies 158 
2.5.1. Experimental set-up 159 
Dissolution experiments were performed with the mini-paddle apparatus and the flow-through 160 
cell apparatus. The mini-paddle apparatus is particularly suitable for working with reduced fluid 161 
volumes, to better mimic intraluminal fluid volumes in the GI tract of paediatric patients [18]. 162 
The flow-through cell apparatus (USP IV apparatus) offers the advantage of easily changing 163 
the medium and flow rate during an experiment, and maintaining sink conditions when operated 164 
in the open mode [19].  165 
The mini-paddle apparatus was equipped with 200 ml vessels and matching paddles, using a 166 
smaller volume compared to adult biorelevant studies [1]. As intestinal motor activity matures 167 
throughout early infancy [20], the agitation rate of the paddle was set at 50 rotations per minute 168 
(RPM). 2 ml samples were removed (with sample replacement) using a 5mL Fortuna Optima® 169 
syringe fitted with stainless tubing and a cannula filter to facilitate representative sampling.  170 
The flow-through cell apparatus was equipped with large cells (22.6 mm diameter), with a 171 
5 mm ruby bead at the bottom of the cell and small glass beads (1 mm diameter) filling the cone 172 
of the cell. Test formulations were placed on a tablet holder. On top of each cell, two filters 173 
were placed; a GF/D and a GF/F filter (Glass Microfibre Filters 24 mm, Whatman™). In all 174 
experiments, the open mode was used. Samples were collected in glass cylinders or Erlenmeyer 175 
flasks, which were weighed to determine the volume of the sample.  176 
Page 10 of 37 
  
All experiments, both in the mini-paddle and the flow-through cell apparatus, were conducted 177 
at 37°C. Sample collection for nifedipine took place at 5, 15, 30, 40, 50, 60, 75, 90 and then 178 
every 30 minutes up to 270 minutes, after the start of the experiment. Sample collection for 179 
lorazepam took place at 5, 15, 30, 45, 60, 75, 90 and 120 minutes after the start of the 180 
experiment. Before HPLC-analysis, samples were filtered through a 0.45 µm RC filter, 181 
discarding the first 10 drops (adsorption of the drugs onto the filters was checked and confirmed 182 
to be negligible). Calibration curves were prepared in corresponding media for each experiment 183 
on the day of the experiment. All experiments were performed in triplicate and in the case of 184 
nifedipine under protection from light. 185 
2.5.2. Screening the impact of patient related variables 186 
To reflect clinical practice in a paediatric hospital with respect to dosage forms, feeding 187 
regimens, and methods of administration, information from standard operating procedures of 188 
the Sophia Children’s Hospital was retrieved. A clinically relevant design of the in vitro 189 
experiments was followed by considering: i. the enteral feeding protocol, ii. the protocol for 190 
administration of medicines through a feeding tube, and iii. the local drug formulary of the 191 
Sophia Childen’s Hospital. The patient relevant parameters studied in the dissolution 192 
experiments were age, prandial state, method of administration, and formulation type. 193 
Even though oral administration is the preferred route to feed paediatric patients, enteral feeding 194 
through a nasogastric tube is often indicated, due to an inability or unwillingness of eating or 195 
swallowing, anorexia, motility problems etc. This mode of administration has implications for 196 
the gastric-emptying rate, which increases with enteral feeding compared to oral feeding [21]. 197 
When possible, breast milk is the preferred type of food for children for a minimum duration 198 
of 4-6 months from the day of birth. Otherwise, patients are fed with formula milk, adjusted to 199 
their energy and protein requirements and potential fluid restriction. Table 2 displays the 200 
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standard neonate and infant formulas administered to enterally fed patients. For normal birth-201 
weight neonates and infants, the feeding interval is gradually reduced from 8 times a day at 202 
birth to 4 times a day at 8 months old. In certain conditions, such as gastroparesis, hyperemesis 203 
or recurrent aspiration, gastric feeding is not suitable and transpyloric feeding directly into the 204 
duodenum is required. Because the duodenum has no reservoir capacity like the stomach, 205 
transpyloric feeding is always administered as a continuous drip.  206 
Administration of solid dosage forms to paediatric patients is often not possible, which means 207 
that the formulation has to be manipulated before administration. In the Sophia Children’s 208 
Hospital, as per protocol, immediate release capsules and tablets are dispersed in an oral syringe 209 
with a small amount of lukewarm water (1-20 ml).  210 
2.5.3. Nifedipine solubility studies 211 
To study the influence of age-related changes in GI fluid composition on compound solubility, 212 
nifedipine solubility studies were performed according to methods described by Maharaj et al. 213 
[4]. In summary, for aqueous based media, an excess amount of nifedipine was added to 2 mL 214 
of medium, dwelled for 24 hours at a shaking water bath at 37°C, filtered through an 0.45 µm 215 
RC filter and diluted with fresh medium prior to HPLC-analysis. For the milk-based media, a 216 
drug extraction step was required, which consisted of a centrifugation step, precipitation of 217 
proteins with methanol, a second centrifugation and filtration of the resulting supernatant 218 
through an 0.45 µm RC filter. All solubility experiments were conducted in triplicate. 219 
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2.5.4. Nifedipine dissolution studies 220 
An overview of the dissolution experiments is given in Table 3. Firstly, pH changes in the fasted 221 
state, resulting from passage through the stomach and small intestine, were simulated in the 222 
mini-paddle apparatus using SGFsp and SIFsp (see section 2.4). The pH shift from the gastric 223 
to the intestinal conditions was achieved by the addition of an equal volume of double 224 
concentrated SIFsp (with additional NaOH), after a simulated gastric residence time of 45 225 
minutes. Secondly, to compare the dissolution of the two nifedipine formulations that are 226 
regularly used in the Sophia Children’s Hospital, commercial nifedipine 10 mg tablets and 227 
compounded 5 mg capsules, an experiment was performed in the flow-through cell apparatus. 228 
To simulate administration to fasted children, adult biorelevant media were used 229 
(FaSSGF/FaSSIF), the gastric residence was set at 30 minutes and the flow rate was reduced 230 
from 5ml/min to 4 ml/min after the medium switch in order to reflect the in vivo gastric and 231 
intestinal conditions (in terms of residence time and volume). The dose of the 10 mg tablets 232 
was matched by using two 5 mg capsules per cell. Thirdly, a dissolution experiment in fasted 233 
state neonatal media (Pn-FaSSGF/FaSSIF) was performed with the flow-through cell apparatus, 234 
in order to reveal the effect of different hydrodynamics compared to the mini-paddle apparatus. 235 
The effects of age-related differences in gastro-intestinal conditions on dissolution were 236 
simulated with the use of neonatal (Pn-FaSSGF/FaSSIF) and infant (Pi-FaSSGF/FaSSIF) 237 
fasting media in the mini-paddle apparatus (see Table 3). To reflect the in vivo conditions in 238 
neonates, the gastric residence time was prolonged, and the gastric volume was decreased 239 
compared to infants [8]. Thirdly, administration through a gastric feeding tube, where the 240 
capsule is dispersed in an oral syringe with 5 ml of warm water before administration, was also 241 
simulated in fasted state neonatal media (Pn-FaSSGF/FaSSIF).  242 
 243 
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2.5.5. Lorazepam dissolution studies 244 
Details of the design of the dissolution studies are presented in Table 3. Dissolution of  the 1 245 
mg tablets was studied in SGFsp and SIFsp and the mini-paddle apparatus, with an increased 246 
rotational speed of 75 rpm to prevent coning of the tablet formulation. This experiment was 247 
repeated using the lorazepam 1 mg/ml oral solution to compare the profiles.  248 
Subsequently, two experiments were conducted with the flow-through cell apparatus. The effect 249 
of prandial state on dissolution was explored using lorazepam 1 mg tablets and infant fasted 250 
state and fed state simulated gastric and intestinal fluids. Pnc-FeSSGF was considered 251 
appropriate to simulate infant fed-state gastric fluid, as it contains milk formula that is given to 252 
infants up to the age of six months. Gastric residence time in the fed state was prolonged 253 
compared to the fasted state and the flow rates were set to reflect the prandial state and gastro-254 
intestinal tract compartment. Administration directly into the duodenum was simulated using 255 
lorazepam 1 mg tablets and infant fed state intestinal fluid (Pi-FeSSIF).  256 
2.6. Analytical quantification 257 
For the quantitative analysis of nifedipine, high performance liquid chromatography combined 258 
with UV (HPLC-UV) detection was used. The method was adapted from the method previously 259 
reported by Vertzoni et al. [22], [23]. Nifedipine was separated on an analytical C18 column 260 
(Thermo Hypersil GOLD, 5 μm, 250 × 4.6 mm) with UV detection at 238 nm, a column 261 
temperature of 30°C, mobile phase of a 60:40 mixture (v/v) of methanol and water (Milli-Q), a 262 
flow rate of 1.0 ml/min, and injection volume of 50 μl. For the quantitative analysis of 263 
lorazepam, the HPLC-UV method as reported by Share  et al. was used [24]. Lorazepam was 264 
separated using a Zorbax SB-C18 analytical column (3.5 μm, 150 × 4.6 mm) with UV detection 265 
at 230 nm, a column temperature of 30°C, mobile phase of a 60:40 mixture (v/v) of methanol 266 
and water (Milli-Q), a flow rate of 0.75 ml/min, and injection volume of 20 μl. Quantification 267 
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of nifedipine and lorazepam was made based on calibration curves constructed from stock 268 
solutions in the corresponding medium (range 0.5-12 µg/ml). For milk- and formula-based 269 
media, calibration curves were created in triplicate, and the same protein precipitation, 270 
centrifugation and filtration process was applied as described in section 2.5.  271 
2.7. Statistical analysis 272 
One-way analysis of variance (ANOVA) with a post-hoc Tukey’s test was applied to identify 273 
statistically significant differences in solubility between adult and age-specific media, using a 274 
significance level of p≤0.05. Statistical analysis was performed in GraphPad Prism version 5.01 275 
for Windows (GraphPad Software, San Diego, CA).  276 
  277 
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3. Results and Discussion 278 
3.1. Paediatric gastrointestinal solubility of nifedipine 279 
Nifedipine is a substance with poor aqueous solubility (around 5-9 µg/ml) [9]. As shown in 280 
Figure 1, nifedipine solubility in adult FaSSGF (3.81 µg/ml) was different to solubility in Pi-281 
FaSSGF (7.04 µg/ml), but not to Pn-FaSSGF (4.99 µg/ml). Although the relativedifference 282 
between the solubility values for adult FaSSGF and Pi-FaSSGF was large, all values were very 283 
similar to the range reported for aqueous solubility. This implies that the small amounts of bile 284 
salts and pepsin present in FaSSGF have a negligible effect on nifedipine solubility, and that 285 
age-related changes in fasted state gastric fluid may be unlikely to significantly influence the 286 
absorption of nifedipine.  287 
Compared to FaSSGF, solubility in FaSSIF was increased. Paediatric investigations examining 288 
luminal fluids within the fasted-state proximal intestine are thus far limited, therefore the 289 
different FaSSIF media were developed to explore the impact of variations in bile salt 290 
concentrations [4]. The nifedipine solubility values that were found in FaSSIF-V2 (12.9 µg/ml), 291 
FaSSIF-50% (9.3 µg/ml) an FaSSIF-150% (15.1 µg/ml) reflected these variations.  292 
In FeSSGF, nifedipine solubility was markedly increased compared to FaSSGF, indicating a 293 
substantial effect of prandial state on nifedipine solubilisation in the gastric fluid. Additional 294 
changes in solubilisation can be expected for energy and/or protein enriched nutrition [25].  295 
The biggest relative differences in solubility between adult and paediatric media were observed 296 
in FeSSIF. Nifedipine solubility in adult FeSSIF-V2 (45.2 µg/ml) was higher than Pi-FeSSIF 297 
(32.1 µg/ml), Pnc-FeSSIF (18.3 µg/ml) and Pnb-FeSSIF 18.5 µg/ml), reflecting the solubilizing 298 
effects of lipids and bile salts.  299 
It should be noted that the solubility of a drug substance in a certain medium is a compound 300 
specific property. Nevertheless, the increased solubility in fed-state media could have some 301 
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implications for clinical practice. Both nifedipine formulations do not have any attributes that 302 
slow or alter the release of the drug substance. The slow dissolution rate of the drug substance 303 
itself is considered to provide the slow onset of action of the drug. In paediatric hypertension, 304 
nifedipine is administered to patients from the age of one month, who are effectively in an 305 
almost continuous fed prandial state. This means that, in these patients, a much more rapid 306 
dissolution from the nifedipine conventional tablets and capsules could be expected, possibly 307 
leading to a shortened Tmax, an increased Cmax and an altered drug exposure , compared to 308 
administration to fasted state patients. An increased Cmax may lead to typical dihydropyridine 309 
adverse effects like headache and flushing. More serious adverse events reported in paediatric 310 
patients possibly caused by nifedipine included change in neurological status, severe 311 
hypotension, and oxygen desaturation [26]. For this reason, the use of immediate release 312 
capsules, filled with a liquid solution of nifedipine, is not recommended in the Netherlands [27].  313 
3.2. Dissolution studies 314 
3.2.1. Nifedipine 315 
The nifedipine dissolution results in both the mini-paddle apparatus and the flow-through cell 316 
apparatus are presented in Figure 2 and Figure 3.  317 
3.2.2. Experimental aspects 318 
Impact of pH - Figure 2A shows the dissolution profile of a 5 mg compounded capsule in SGF 319 
sp and SIF sp in the mini-paddle apparatus. As nifedipine is unionisable in the gastro-intestinal 320 
pH range, no apparent effect on nifedipine’s dissolution from the pH switch was observed. A 321 
plateau was reached after around 180 minutes, with just over 20% of nifedipine dissolved. After 322 
the media switch, a rise in the amount dissolved was observed, resulting from an increased 323 
volume of dissolution medium. The large variability in the early phase of the experiment was 324 
caused by a variable capsule rupture time.   325 
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Impact of formulation - The dissolution profiles of the commercial 10 mg nifedipine tablets and 326 
the compounded nifedipine 5 mg capsules in FaSSGF/FaSSIF-V2 (simulating children) in the 327 
flow-through cell apparatus (displayed in Figure 2B) show a similar dissolution/release pattern, 328 
but the dissolution extent and rate from the capsules were slightly higher. As mentioned before, 329 
both formulations are presented as slow release formulations, even though they are not 330 
formulated as such. The dissolution profiles do confirm this assumption under fasted conditions, 331 
however, from our results, the capsules and tablets cannot be considered interchangeable, as 332 
they previously were [28]. 333 
Impact of hydrodynamics - Figure 2C shows the dissolution profiles of nifedipine 1 mg 334 
compounded capsules in Pi-FaSSGF/FaSSIF in the mini-paddle and the flow-through cell 335 
apparatus. The extent of nifedipine dissolution was affected by the type of in vitro dissolution 336 
apparatus used. Dissolution of nifedipine 1 mg capsules in the mini-paddle apparatus reached 337 
a plateau of 40% after around two hours, due to the lack of sink conditions, whereas in the flow-338 
through cell apparatus a continuous dissolution of nifedipine was observed with 70% dissolved 339 
at 270 min. Due to the continuous flow of fresh medium, sink conditions were achieved when 340 
the system operated in the open-loop configuration. In this way, the dissolution rate reflects the 341 
behaviour of the formulation and not the solubility of the substance, as in the closed systems 342 
[19]. 343 
3.2.3. Patient related aspects 344 
Impact of age - Figure 3A shows the dissolution profiles of 1 mg compounded capsules in Pn-345 
FaSSGF/FaSSIF-V2 and Pi-FaSSGF/FaSSIF-V2 in the mini-paddle apparatus. Between the 346 
dissolution profiles, a small effect of age was observed due to the difference in gastric emptying 347 
time/media switch, but an overall similar extent of dissolution was seen at the end of the 348 
experiment. This was an expected result as dissolution conditions with regard to fluid 349 
composition only moderately differed in the gastric phase. The gastric release was again 350 
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variable and low in both experiments, as a result of a variable capsule rupture time. Also, the 351 
bile salt content, an important constituent to nifedipine solubility, is much lower in (paediatric) 352 
FaSSGF compared to FaSSIF-V2 [4].  353 
Impact of method of administration - Figure 3B shows the dissolution profiles of nifedipine 354 
compounded capsules administered intact vs. capsule content dispersed in water before 355 
administration in Pn-FaSSGF (45 min) and FaSSIF-V2 in the mini-paddle apparatus. The 356 
amount released was slightly higher in the gastric phase in the case that the capsule content had 357 
been mixed with water before administration compared to the direct administration of the 358 
capsule, and profiles in the intestinal phase were similar (Figure 2B). Since absorption mainly 359 
takes place from the small intestine and onwards, this suggests that a large change in the rate 360 
and extent of absorption from the different mode of administration of the capsule is unlikely 361 
[29].  362 
3.3. Lorazepam 363 
The lorazepam dissolution results under paediatric biorelevant conditions in both the mini-364 
paddle apparatus and the flow-through cell apparatus are presented in Figure 4.  365 
3.3.1. Experimental aspects 366 
Impact of pH and formulation -  Performance of the lorazepam oral solution  and tablet 367 
formulation was assessed in SGF sp and SIF sp with the mini-paddle apparatus (Figure 4A). 368 
During the simulated gastric residence time (45 min), almost all lorazepam was dissolved from 369 
the tablet, reaching similar concentrations as compared to the lorazepam liquid after only 15 370 
minutes.  371 
3.3.2. Patient related aspects 372 
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Impact of prandial state - Results from the flow-through cell apparatus dissolution studies 373 
depicted in Figure 4B show the dissolution profiles of lorazepam 1 mg tablets in Pi-374 
FaSSGF/FaSSIF-V2 and Pnc-FeSSGF/Pi-FeSSIF. A slower dissolution rate was observed in 375 
fasted state conditions, leading to a lower amount dissolved  after two hours (81.3% +/- 8.4%) 376 
compared to fed state conditions (95.3% +/-3.0%). This could be predictive of a slower rate of 377 
in vivo drug absorption. Nevertheless, this is a relatively small difference, considering that 378 
lorazepam is likely to be absorbed almost completely, as is known from adult data [30].. 379 
Impact of method of administration - Sometimes a patient does not tolerate gastric feeding and 380 
transpyloric feeding directly into the duodenum is required. When necessary, medication is also 381 
administered through the duodenal feeding tube and solid dosage forms are crushed or 382 
dispersed. When direct administration of the lorazepam tablet to the duodenum was simulated 383 
in Pi-FeSSIF in the flow-through cell apparatus, the dissolution profile was similar to the one 384 
obtained in Pnc-FeSSGF/Pi-FeSSIF (Figure 4C). These results suggest that administration 385 
through a duodenal feeding tube will not impact the in vivo dissolution. A change in tmax is still 386 
possible however, as lorazepam reaches the site of absorption, namely the upper intestine, more 387 
quickly than when it is administered orally or via a gastric feeding tube. 388 
  389 
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4. General discussion 390 
This study has yielded information on the application of nifedipine and lorazepam products in 391 
paediatric pharmacotherapy based on biopharmaceutical in vitro investigations.  392 
As mentioned in section 3.1, markedly increased or accelerated absorption of nifedipine could 393 
lead to adverse effects such as severe hypotension, and must be avoided. In the solubility 394 
studies, we observed a significant food effect on the solubility of nifedipine in paediatric media, 395 
which is in agreement with previously reported clinical data in adults [32]. This expected impact 396 
of food is also applicable in paediatric patients, and needs to be taken into account when 397 
administering nifedipine to paediatric patients. Clinicians should be aware that they cannot rely 398 
on the slow onset of action associated with nifedipine when conventional capsules or tablets 399 
are administered to patients in the fed state. Reassuring results came from the experiment 400 
dispersing the nifedipine capsule in water before administration, a commonly applied 401 
administration technique, revealing no significant differences in dissolution and thus implying 402 
no altered bioavailability in comparison to administration of the intact capsule.  403 
In our experiments, dissolution of the lorazepam tablets was affected to a small extend by the 404 
different experimental set-ups, namely the simulated prandial state and administration site. As 405 
there are no indications that lorazepam is a substrate to gastro-intestinal drug transporters, and 406 
absorption is almost complete in adults [30], it is also unlikely that excipients from the oral 407 
liquid will alter the lorazepam absorption compared to the tablets. When administering 408 
lorazepam to PICU patients to prevent iatrogenic withdrawal syndrome, precise dosing is 409 
required [15]. For this reason, and for ease of administration through a feeding tube, a liquid 410 
formulation would be the dosage form of choice. The fast and complete dissolution of the tablets 411 
gives reassurance about the interchangeability of liquid versus immediate release lorazepam 412 
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tablets, and are supplemented with negligible effects of prandial state and administration site 413 
on the in vitro performance of the lorazepam formulations.   414 
Drug substance solubility, together with the highest dose, upper GI lumen fluid volume, and 415 
volume used for administration are key factors defining the solubility classification of a drug 416 
within the BCS. The adult BCS is widely used in support of waivers of in vivo bioequivalence 417 
studies for immediate release solid oral formulations containing BCS class I and III (high 418 
solubility) substances, but it has been recognised that  BCS classifications do not necessarily 419 
translate to paediatric populations [33]. When the dose number (D0) of nifedipine is calculated 420 
using the age adjusted initial gastric volumes (V0) proposed by Shawahna [34] and the saturated 421 
solubility values (Cs) measured for Pnc-FeSSGF, dosages up to 0.22 mg/kg would result in a 422 
D0 < 1, and thus be considered BCS I. This example illustrates one of the challenges of 423 
developing a relevant paediatric BCS.  424 
Ideally, the results obtained from in vitro dissolution experiments would be integrated into more 425 
complex in silico prediction models, which are able to include other factors influencing 426 
absorption, like gastric emptying. This physiologically based pharmacokinetic (PBPK) 427 
modeling and simulation is already commonly used in formulation development/bridging for 428 
adult medicines and provides a promising tool for paediatric in vivo drug performance 429 
prediction, provided we gain a better understanding of the developmental changes of the 430 
gastrointestinal tract in the paediatric population [3]. Aside from the factors influencing in vivo 431 
dissolution, specific research is still required on the factors influencing permeability, mainly 432 
the ontogeny of metabolizing enzymes and drug transporters, to better predict oral drug 433 
absorption in this population [35]. Ultimately, the developed biopharmaceutical tools could be 434 
validated using paediatric pharmacokinetic data, when available and possible to be shared by 435 
the pharmaceutical industry. The validated biopharmaceutical tools can then be used to study 436 
off-patent paediatric drugs that would otherwise be neglected.  437 
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There is still a knowledge gap concerning GI physiology in paediatric patients. With the 438 
development of the paediatric biorelevant media, extrapolations from adult values had to be 439 
made for some aspects when availability of paediatric data was limited [4]. Future adaptations 440 
of the media compositions are therefore likely, when clinical investigations yield more accurate 441 
paediatric values. Other aspects that would gain from future clinical information and would be 442 
further updated in the design of in vivo predictive dissolution tests for the paediatric population 443 
would relate to the fluid volumes available at the gastro-intestinal lumen, and the motility 444 
patterns and hydrodynamics.  445 
5. Conclusion 446 
The in vitro results obtained from the experiments in this study, designed to reflect clinical 447 
practice in a paediatric hospital, suggest that biorelevant solubility and dissolution studies could 448 
assist in the understanding of drug performance in paediatric patients. The dissolution setups 449 
aiming to simulate physiological conditions to address numerous different administration 450 
scenarios, which would not be feasible or ethical in pharmacokinetic studies in children.  451 
  452 
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Table 1 Adult and paediatric biorelevant media used in solubility and dissolution experiments 543 
[4], [5], [16], [17] 544 
 Fasted-state Simulated Gastric Fluid
    
Fed-state Simulated Gastric Fluid 
  
 




























80 20 60        
Lecithin (uM) 20 5 15        
Pepsin 
(mg/mL) 
0.1 0.015 0.025        
Acetic Acid 
(mM) 
      17.12 7.25 7.25  
Sodium 
Acetate (mM) 
      29.75 64.65 64.65  
Milk:buffer       1:1 1:1 1:1  
HCl/NaOH qs pH 1.6 pH 1.6 pH 1.6 pH 5 pH 5.7 pH 5.7  
               














- - - 25 15 15  
 Fasted-state Simulated Intestinal 
Fluid    
Fed-state Simulated Intestinal Fluid  
  































3 1.5 4.5 10 2.5 2.5 7.5 
Lecithin (mM) 0.2 0.1 0.3 2 0.5 0.5 1.5 





68.62 68.62  68.62  125.5 95 111.73 107.35 
Maleic acid 
(mM) 








      0.8 0.8 1.06 0.8 
                
HCl/NaOH qs pH 6.5 pH 6.5 pH 6.5 pH 5.8 pH 5.8 pH 5.8 pH 5.8 
Osmolarity 
(mOsm/kg) 




300 +/- 10 330 +/- 10 330 +/- 10 390 +/- 10 
Buffering 
Capacity 




P=paediatric, i = infant, n = neonate, c = cow milk formula, s = soy milk formula, b = breast 545 
fed 546 
 547 
Table 2 Neonate and infant nutrition   548 
 PICU non ventilated PICU ventilated 















2-3.5 0-1 Nenatal 
Start 
78 kcal  
2.5 g protein  
Nenatal Start 
18% w/v 
87 kcal  
2.7 g protein  
Nenatal Start 18% 
w/v + 0.5% NPF 
89 kcal  
3.2 g eiwit  
3.5-8  0-6  Nutrilon® 
1 
66 kcal  
1.3 g protein  
Nutrilon® 1 
17% w/v 
82 kcal  
1.6 g protein  
Infatrini® 100 kcal  
2.6 g protein  
8 - 9.5 7-9  Nutrilon® 
2 
68 kcal  
1.4 g protein  
Nutrilon® 2 
17% w/v 
79 kcal  
1.6 g protein  
Infatrini® 100 kcal  
2.6 g protein  
9.5 – 10.5 10-12  Nutrilon® 
3 
70 Kcal  
1,5 g protein  
Nutrilon® 3 
17% w/v 
79 kcal  
1.7 g protein  
Infatrini® 100 kcal  
2.6 g protein  
Nutrilon® = Aptamil® first milk, NPF= Nutrilon® Nenatal Protein Fortifier, PICU = 549 
paediatric intensive care unit 550 
All products are manufactured by Danone (Paris, France)  551 
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Table 3 Parameters used for the dissolution experiments in the mini-paddle and the flow-through-cell apparatus (USP IV apparatus). 552 
    Gastric Conditions Intestinal conditions  
Apparatus API Formulation Agitation (rpm) Medium pH Volume (ml) Time (min.) Medium pH Volume (ml) Time (min.) Total Volume (ml) 
Mini-paddle Nifedipine Capsule 5 mg  50 SGFsp 1.2 100 45 SIF sp 
6.
8 100 225 200 
  Capsule 1 mg  50 Pn-FaSSGF 1.6 50 45 FaSSIF  
6.
5 150 225 200 
  Capsule 1 mg  50 Pi-FaSSGF 1.6 75 30 FaSSIF  
6.
5 125 240 200 
  Capsule 1 mg, dissolved in syringe  50 Pn-FaSSGF 1.6 50 45 FaSSIF  
6.
5 150 225 200 
 
Lorazepa
m Oral solution 1 ml (1 mg/ml)  75 SGFsp 1.2 100 45 SIF sp 
6.
8 100 75 200 
  Tablet 1mg  75 SGFsp 1.2 100 45 SIF sp 
6.
8 100 75 200 
        Medium pH 
Flow 
(ml/min) Time (min.) Medium pH 
Flow 
(ml/min) Time (min.) Total Volume (ml) 
Flow-through 
cell Nifedipine Capsule 1mg  Pi-FaSSGF 1.6 4 30 FaSSIF 
6.
5 3 240 840 
  Capsule 2x5 mg  FaSSGF 1.6 5 30 FaSSIF 
6.
5 4 240 1110 
  Tablets retard  10 mg  FaSSGF 1.6 5 30 FaSSIF 
6.
5 4 240 1110 




m Tablet 1mg  Pi-FaSSGF 1.6 4 30 FaSSIF 
6.
4 3 90 390 




8 5 60 600 




8 5 120 600 
API = active pharmaceutical ingredient, rpm = rotations per minute  553 
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Figure 1 Nifedipine 24h solubility (mean±SD, n=3) in adult and paediatric biorelevant 554 
gastrointestinal media. Statistically significant solubility differences compared to the adult 555 
media are denoted with * (p≤0.05) or *** (p≤0.001). p=paediatric, i = infant, n = neonate, c = 556 
cow milk formula, s = soy milk formula, b = breast fed 557 
Figure 2 Dissolution profiles of nifedipine (mean±SD, n=3) under different conditions A: 558 
nifedipine 5 mg compounded capsules in SGF sp (45min)/SIF sp (225 min), mini-paddle 559 
apparatus (50 rpm), B: nifedipine 10 mg commercial tablets (black circels) vs. 2x5mg 560 
compounded capsules (grey squares) in FaSSGF (30 min, 5 ml/min)/FaSSIF (240 min, 4 561 
ml/min), flow-through cell apparatus, C: nifedipine 1 mg compouded capsules in Pi-FaSSGF 562 
(30 min)/FaSSIF(240 min) in the mini-paddle apparatus (50 rpm) and the flow-through cell 563 
apparatus (4 ml/min and 3 ml/min) (mean±SD, n=3). Dotted lines represent the time of medium 564 
change. 565 
Figure 3 Dissolution profiles of nifedipine (mean±SD, n=3) under different conditions A: 566 
nifedipine 1 mg compounded capsules in Pn-FaSSGF (45 min)/ FaSSIF-V2 (225 min) (black 567 
circels) and Pi-FaSSGF (30 min)/FaSSIF-V2 (240 min) (grey squares), mini-paddle apparatus 568 
(50 rpm), B: nifedipine 1 mg compounded capsules administered intact (black circels) vs. 569 
capsule content dispersed in water before administration (grey squares), in Pn-FaSSGF (45 570 
min)/FaSSIF-V2 (225 min), mini-paddle apparatus (50 rpm). Dotted lines represent the time of 571 
medium change. 572 
Figure 4 Dissolution profiles of lorazepam (mean±SD, n=3) under different conditions. A: 1 573 
mg commercial tablet (black circles) vs. 1 ml compounded oral solution 1 mg/ml (grey squares), 574 
SGF sp (45 min)/SIF sp (75 min), mini-paddle apparatus (75rpm)  B: 1 mg commercial tablets, 575 
fasted-state Pi-FaSSGF (30 min, 4 ml/min)/FaSSIF-V2 (90 min, 3 ml/min) vs. fed-state Pn-576 
FeSSGF (60 min, 5 ml/min)/Pi-FeSSIF (60 min, 5 ml/min), flow-through cell apparatus, C: 1 577 
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mg commercial tablets, regular administration Pn-FeSSGF (60 min, 5 ml/min)/Pi-FeSSIF (60 578 
min, 5 ml/min) vs. duodenal administration Pi-FeSSIF (120 min, 5 ml/min), flow-through cell 579 
apparatus. Dotted lines represent the time of medium change. 580 
 581 
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